- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
John Shamsey, Bristol-Myers Squibb
S
John Shamsey
Senior director, managed markets strategy, Bristol-Myers Squibb
ACTIVE IN: Academy of Managed Care Pharmacy
USES: Longitudinal data to develop national account strategies
Medicare Part D had a significant impact on the industry, but John Shamsey, age 39, was ready for it. He had focused on managed markets early in his career, becoming versed in the intricacies of payers while his marketing colleagues considered the it an afterthought. As a result, Shamsey has become an unofficial spokesperson for Part D, explaining to colleagues in the company and the rest of the industry just how the whole thing works.
John Shamsey
"It gave me a chance to offer insight to others about what Medicare means to our current product portfolio, as well as for future products' value proposition development," says Shamsey. "The impact that managed markets and payers are having on our business will be really important for leaders to understand and to incorporate the perspective into the business."
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
